CLDX Q3 2023 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+272.7% YoY

Gross Profit

$750,00049.4% margin

Operating Income

-$41M-2718.5% margin

Net Income

-$38M-2522.1% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+466.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$280M

Total Liabilities

$34M

Stockholders' Equity

$247M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$407,000	+272.7%
Gross Profit	$750,000	-$21M	+103.5%
Operating Income	-$41M	-$28M	-48.9%
Net Income	-$38M	-$27M	-42.8%

Revenue Segments

Grant

$2M100%

Service

$2,0000%